The Effect of Practolol (‘Eraldin’) in the Long-Term Treatment of Severe and Moderate Hypertension

1973 ◽  
Vol 45 (s1) ◽  
pp. 167s-170s ◽  
Author(s):  
R. M. Fulton ◽  
E. Hilda Fulton ◽  
K. G. Green
Keyword(s):  
Moderate Hypertension ◽  
Severe Hypertension ◽  
Term Treatment ◽  
Blood Levels ◽  
Safety Factors ◽  
First Choice ◽  
Long Term Treatment ◽  
Additional Safety

1. The results of a clinical trial of practolol in sixty-one patients with moderate and severe hypertension are presented. Alone or with a diuretic the drug was highly effective in thirty patients, and in a further eight who developed side effects. Effectiveness was not directly related to dosage or blood levels of drug, or to the severity of the hypertension. 2. Nine non-responders to practolol were found to respond to propranolol which is probably a more widely effective antihypertensive agent. Nevertheless, the additional safety factors of practolol and twice daily dosing make it first choice for many patients. We have been impressed by the ability of both β-blocking drugs to control blood pressure without impairing the quality of every-day life.

Prophylaxis in people with haemophilia

2009 ◽  
Vol 101 (04) ◽  
pp. 674-681 ◽  
Author(s):  
Massimo Franchini ◽  
Annarita Tagliaferri ◽  
Antonio Coppola
Keyword(s):  
Quality Of Life ◽  
Cost Benefit ◽  
Primary Prophylaxis ◽  
Secondary Prophylaxis ◽  
Severe Haemophilia ◽  
Duration Of Treatment ◽  
First Choice ◽  
Long Term Treatment

SummaryA four-decade clinical experience and recent evidence from randomised controlled studies definitively recognised primary prophylaxis, i.e. the regular infusion of factor concentrates started after the first haemarthrosis and/or before the age of two years, as the first-choice treatment in children with severe haemophilia. The available data clearly show that preventing bleeding since an early age enables to avoid or reduce the clinical impact of muscle-skeletal impairment from haemophilic arthropathy and the related consequences in psycho-social development and quality of life of these patients. In this respect, the aim of secondary prophylaxis, defined as regular long-term treatment started after the age of two years or after two or more joint bleeds, is to avoid (or delay) the progression of arthropathy. The clinical benefits of secondary prophylaxis have been less extensively studied, especially in adolescents and adults; also in the latter better outcomes and quality of life for earlier treatment have been reported. This review summarises evidence from literature and current clinical strategies for prophylactic treatment in patients with severe haemophilia, also focusing on challenges and open issues (optimal regimen and implementation, duration of treatment, long-term adherence and outcomes, cost-benefit ratios) in this setting.

PRAZOSIN: LONG‐TERM TREATMENT OF MODERATE AND SEVERE HYPERTENSION AND LACK OF “TOLERANCE”

1981 ◽  
Vol 2 (3) ◽  
pp. 146-147 ◽  
Author(s):  
Rowan G. Walker ◽  
Judith A. Whitworth ◽  
Dianne Saines ◽  
Priscilla Kincaid‐Smith
Keyword(s):  
Severe Hypertension ◽  
Term Treatment ◽  
Long Term Treatment

scholarly journals Distribution of strontium and mineralization in iliac bone biopsies from osteoporotic women treated long-term with strontium ranelate

2011 ◽  
Vol 165 (3) ◽  
pp. 469-476 ◽  
Author(s):  
Audrey Doublier ◽  
Delphine Farlay ◽  
Mohamed T Khebbab ◽  
Xavier Jaurand ◽  
Pierre J Meunier ◽  
...  
Keyword(s):  
Bone Mineralization ◽  
Progressive Increase ◽  
Tissue Level ◽  
Term Treatment ◽  
Iliac Bone ◽  
X Ray ◽  
Long Term Treatment ◽  
Bone Biopsies

ObjectiveTo investigate interactions between strontium (Sr) and bone mineral and its effects on mineralization in osteoporotic women treated long-term with Sr ranelate (SrRan).DesignIn this study, 34 iliac bone biopsies were analyzed after 2, 12, 24, 36, 48, and 60 months of treatment with SrRan.MethodsSr global distribution was analyzed by X-ray cartography and the percentage of bone area containing Sr was calculated in the bone samples. The focal distribution of Sr in all bone samples was investigated by X-ray microanalysis. The degree of mineralization was assessed by quantitative microradiography.ResultsAbsent from old bone formed before the beginning of treatment, Sr was exclusively present in bone formed during this treatment with a much higher focal Sr content in new bone structural units than in old ones. A progressive increase in the extent of areas containing Sr was observed during treatment. The focal bone Sr content in recently formed bone was constant over treatment. Secondary mineralization was maintained at a normal level during treatment.ConclusionThus, the quality of bone mineralization (density and heterogeneity at tissue level) was preserved after a long-term treatment with SrRan.

The crystal arthropathies

2013 ◽  
Vol 6 (11) ◽  
pp. 681-687 ◽  
Author(s):  
Robert A Jones ◽  
Brian Quilty
Keyword(s):  
Quality Of Life ◽  
Risk Factors ◽  
Inflammatory Arthritis ◽  
Term Treatment ◽  
Routine Practice ◽  
Treatment Goals ◽  
Crystal Arthropathies ◽  
Long Term Treatment

Unlike many other forms of inflammatory arthritis, the crystal arthropathies are routinely diagnosed and managed in primary care. Gout, in particular, is relatively commonplace and rates of other types of crystal-related arthritis are predicted to increase. These are, therefore, conditions that GPs and trainees will regularly encounter during routine practice. While the clinical features and pathophysiology of gout and pseudo-gout are well described, the long-term treatment goals and options of management are often less well understood, and opportunities to assess for associated co-morbidities can easily be missed. GPs can be central in optimising management by promptly and appropriately addressing acute symptoms, preventing recurrent attacks, minimising disability and work absences, reducing cardiovascular risk factors, improving general health and enhancing quality of life.

scholarly journals Concerns and Quality of Life of Cancer Survivors Across the Survivorship Trajectory: A Singapore Perspective

2019 ◽  
Author(s):  
Gek Phin Chua ◽  
Quan Sing Ng ◽  
Hiang Khoon Tan ◽  
Whee Sze Ong
Keyword(s):  
Quality Of Life ◽  
Cancer Survivors ◽  
Cancer Treatment ◽  
Cancer Survivorship ◽  
Recurrence Risk ◽  
Term Treatment ◽  
Fear Of Recurrence ◽  
Long Term Treatment

Abstract Background The aim of this study is to determine the main concerns of survivors at various stages of the cancer survivorship of the cancer survivorship trajectory and to assess whether these concerns have any effect on their quality of life (QOL). The overall goal was to use the insights from the study to guide practice on patient care. Methods A cross-sectional survey of 1107 cancer survivors diagnosed with colorectal, breast, lung, gynaecological, prostate or liver cancers from a cancer centre in Singapore. Eligible patients self-completed a questionnaire adapted from the Mayo Clinic Cancer Centre’s Cancer Survivors Survey of Needs. Results The top 5 concerns among all survivors were cancer treatment and recurrence risk (51%), followed by long-term treatment effects (49%), fear of recurrence (47%), financial concerns (37%) and fatigue (37%). Cancer treatment and recurrence risk, long-term treatment effects and fear of recurrence were amongst the top concerns across the survivorship trajectory. Mean QOL was 7.3 on a scale of 0 – 10. Completed treatment patients had higher QOL score than the newly diagnosed and on treatment patients and the patients dealing with recurrence or second cancer patients. Predictors for QOL included the economic status and housing type of patients and whether patients were concerned with pain and fatigue Conclusion This study confirms that cancer survivors in Singapore face multiple challenges and had various concerns at various stages of cancer survivorship, some of which negatively affect their QOL It is critical to design patient care delivery that appropriately address the various concerns of cancer survivors in order for them to cope and improve their QOL.

scholarly journals Effects of long-term treatment with Dienogest on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain

2019 ◽  
Vol Volume 12 ◽  
pp. 2371-2378 ◽  
Author(s):  
Salvatore Caruso ◽  
Marco Iraci ◽  
Stefano Cianci ◽  
Salvatore Giovanni Vitale ◽  
Valentina Fava ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Sexual Function ◽  
Pelvic Pain ◽  
Term Treatment ◽  
Long Term Treatment

Long term treatment of moderate hypertension with the beta1-receptor blocking agent metoprolol

1977 ◽  
Vol 11 (4) ◽  
pp. 247-254 ◽  
Author(s):  
B. -G. Hansson ◽  
J. -F. Dymling ◽  
P. Manhem ◽  
B. H�kfelt
Keyword(s):  
Moderate Hypertension ◽  
Blocking Agent ◽  
Term Treatment ◽  
Receptor Blocking ◽  
Long Term Treatment

Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer

2004 ◽  
Vol 40 (11) ◽  
pp. 1704-1712 ◽  
Author(s):  
I.J Diel ◽  
J.-J Body ◽  
M.R Lichinitser ◽  
E.D Kreuser ◽  
W Dornoff ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Bone Disease ◽  
Term Treatment ◽  
Metastatic Bone Disease ◽  
Long Term Treatment
Sign in / Sign up

Export Citation Format

Share Document